The development of a DNA microarray-based assay for the characterization of commercially formulated microbial products

Journal of Microbiological Methods
J W DuboisRoland Brousseau

Abstract

Commercially formulated bioproducts containing a complex consortia of bacteria as an active ingredient pose a significant challenge for regulatory agencies and companies seeking to assess the safety and efficacy of these bioproducts. The main challenge stems from how to characterize the bacterial composition of these products, for which there is presently a lack of suitable methods. A prototype DNA microarray composed of oligonucleotide probes for functional genes, virulence factors, and taxonomic genes for a number of bacterial species was developed to examine the utility of microarray technology as a molecular tool for characterizing consortia bioproducts. The genomic DNA from four different products was extracted by two methods and examined with the microarray prototype and by denaturing gradient gel electrophoresis (DGGE). Although the identity of the consortial species remains unknown, the microarray assay provided unique and reproducible hybridization patterns for all four products, and agreed with the fingerprints generated by DGGE. The ability to differentiate between a variety of consortia products demonstrates that DNA microarrays have the potential to be a powerful tool in monitoring complex microbial communities.

References

Jan 10, 2002·Applied Microbiology and Biotechnology·H Shan, J P Obbard
Jan 7, 2003·Applied and Environmental Microbiology·R TemmermanJ Swings
Mar 26, 2003·Journal of Microbiological Methods·Douglas R CallFrank J Loge

❮ Previous
Next ❯

Citations

Jul 14, 2012·Folia Microbiologica·Christos StefanisEugenia Bezirtzoglou
Jun 9, 2005·Journal of Microbiological Methods·Saleema Saleh-LakhaJack T Trevors
Aug 6, 2005·Journal of Clinical Microbiology·Philippe GiammarinaroRegine Talon
Jan 27, 2007·Microbial Cell Factories·Pratik JaluriaJoseph Shiloach
Jun 2, 2009·Journal of Microbiological Methods·Maria Laura GianninoFabio Fracchetti
Dec 26, 2006·Journal of Microbiological Methods·Jean-Christophe AvarreGilles Béna
Jan 4, 2012·Extremophiles : Life Under Extreme Conditions·J T TrevorsL Van Overbeek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.